Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914

Biochemical, physiological and medical aspects of ubiquinone function

Ernster, L., & Dallner, G. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00028-3 · Cited by 1,246

Abnormalities of the electron transport chain in idiopathic parkinson's disease

Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061

The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it

Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927

Oxygen radicals and the nervous system

Halliwell, B. B., & Gutteridge, J. M. C. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90010-4 · Cited by 823

Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease

Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435

Lovastatin decreases coenzyme Q levels in humans.

Folkers, K., Langsjoen, P. H., Willis, R. A., Richardson, P. C., Xia, L., Ye, C. Q., & Tamagawa, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.22.8931 · Cited by 426

Platelet mitochondria function in Parkinson's disease

Krige, D., Carroll, M. T., Cooper, J. A. D., MARSDEN, C. D., & Schapira, A. H. V. (1992) · Annals of Neurology · doi:10.1002/ana.410320612 · Cited by 358

Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes

Benecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220

A Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q10 (Ubiquinone)

Constantinescu, R., McDermott, M. P., DiCenzo, R., de Blieck, E. A., Hyson, H. C., Beal, M. F., Bednarczyk, E. M., Bogdanov, M. B., Metakis, L., Browne, S. E., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007307571 · Cited by 27

Serum cholesterol levels and the risk of multiple system atrophy: A case‐control study

Lee, P. H., Lim, T. S., Shin, H., Yong, S. W., Nam, H. S., & Sohn, Y. H. (2009) · Movement Disorders · doi:10.1002/mds.22459 · Cited by 27

Identification of ataxia‐associated mtDNA mutations (m.4052T>C and m.9035T>C) and evaluation of their pathogenicity in transmitochondrial cybrids

Sikorska, M., Sandhu, J. K., Simon, D. K., Pathiraja, V., Sodja, C., Li, Y., Ribecco‐Lutkiewicz, M., Lanthier, P. H., Borowy‐Borowski, H., Upton, A. R. M., et al. (2009) · Muscle & Nerve · doi:10.1002/mus.21355 · Cited by 28

Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population

Varghese, M., Pandey, M., Samanta, A., Gangopadhyay, P. K., & Mohanakumar, K. P. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.12.021 · Cited by 26

Serum cholesterol, use of lipid‐lowering drugs, and risk of Parkinson disease

de Lau, L. M. L., Stricker, B. H. C., & Breteler, M. M. B. (2007) · Movement Disorders · doi:10.1002/mds.21582 · Cited by 26

Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein

Li, G., Zou, L., Jack, C. R., Yang, Y., & Yang, E. S. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.005 · Cited by 25

MPTP Parkinsonism and Implications for Understanding Parkinson's Disease

Alshimemeri, S. A., Luca, D. G. D., & Fox, S. H. (2021) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13344 · Cited by 24

Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic Coenzyme Q10 pretreatment

Binukumar, B. K., Gupta, N., Bal, A., & Gill, K. D. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.07.015 · Cited by 23

Morinda citrifoliamitigates rotenone-induced striatal neuronal loss in male Sprague-Dawley rats by preventing mitochondrial pathway of intrinsic apoptosis

Narasimhan, K. K. S., Jayakumar, D., Saraswathi, U., Mohan, T., Sathyamoorthy, Y. K., Ezhil, P., & Kalaiselvi, P. (2016) · Redox Report · doi:10.1080/13510002.2016.1253449 · Cited by 23

An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders

Camins, A., Sureda, F. X., Junyent, F., Verdaguer, E., Folch, J., Beas‐Zárate, C., & Pallàs, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003781898 · Cited by 24

Energy Status, Ubiquitin Proteasomal Function, and Oxidative Stress During Chronic and Acute Complex I Inhibition with Rotenone in Mesencephalic Cultures

Zeevalk, G. D., & Bernard, L. P. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.662 · Cited by 23

Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson’s disease

Isobe, C., Murata, T., Sato, C., & Terayama, Y. (2007) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2005.12.023 · Cited by 22

Determination of urinary coenzyme Q 10 by HPLC with electrochemical detection: Reference values for a paediatric population

Yubero, D., Montero, R., López-Ramos, M. G., Neergheen, V., Navas, P., Artuch, R., & Hargreaves, I. P. (2015) · BioFactors · doi:10.1002/biof.1242 · Cited by 22

Protective Efficacy of Coenzyme Q10 Against DDVP-Induced Cognitive Impairments and Neurodegeneration in Rats

Binukumar, B. K., Gupta, N., Sunkaria, A., Kandimalla, R. J. L., Wani, W. Y., Sharma, D. R., Bal, A., & Gill, K. D. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9289-0 · Cited by 22

Biosynthesis, Deficiency, and Supplementation of Coenzyme Q

Staiano, C., García‐Corzo, L., Mantle, D., Turton, N., Millichap, L. E., Brea‐Calvo, G., & Hargreaves, I. P. (2023) · Antioxidants · doi:10.3390/antiox12071469 · Cited by 25

Role of Autophagy in Parkinson’s Disease

Grace, G. Y., Zhang, C., & Lim, K. (2013) · InTech eBooks · doi:10.5772/54927 · Cited by 21

Parkinson's disease: emerging pharmacotherapy

Strecker, K., & Schwarz, J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802596906 · Cited by 21

Parkinson's Disease: Genetics and Pathogenesis

Testa, C. M. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn063 · Cited by 21

Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection

Fash, D. M., Khdour, O. M., Sahdeo, S., Goldschmidt, R., Jaruvangsanti, J., Dey, S., Arce, P. M., Collin, V. C., Cortopassi, G. A., & Hecht, S. M. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.075 · Cited by 19

Emerging drugs for Parkinson’s disease

Morgan, J. C., & Sethi, K. D. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.403 · Cited by 19

Clinical trials aimed at detecting neuroprotection in Parkinson’s disease

Hauser, R. A., & Zesiewicz, T. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s58 · Cited by 19

Neuroimaging in Primary Coenzyme-Q10-Deficiency Disorders

Münch, J., Prasuhn, J., Laugwitz, L., Fung, C., Chung, B. H., Bellusci, M., Mayatepek, E., Klee, D., & Distelmaier, F. (2023) · Antioxidants · doi:10.3390/antiox12030718 · Cited by 18

Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease

Bronstein, J. M., Paul, K. C., Yang, L., Haas, R., Shults, C. W., Le, T. P., & Ritz, B. R. (2015) · Movement Disorders · doi:10.1002/mds.26164 · Cited by 18

Response: Parkinson's disease, pesticides and mitochondrial dysfunction

Greenamyre, J. T., Betarbet, R. S., Sherer, T., & Panov, A. V. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01788-4 · Cited by 18

Complementary Therapies for Parkinson's Disease: What's Promoted, Rationale, Potential Risks and Benefits

Rabin, M., Stevens‐Haas, C., Havrilla, E., Rosenstein, A. K., Toffey, B., Devi, T., Earnhardt, M. C., & Kurlan, R. (2015) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12170 · Cited by 17

Toxin-induced mitochondrial dysfunction

Browne, S. E., & Beal, M. F. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53010-5 · Cited by 17

Iron(ing) out parkinsonisms: The interplay of proteinopathy and ferroptosis in Parkinson's disease and tau-related parkinsonisms

Caiado, M. J. D. C., Dolga, A. M., & den Dunnen, W. F. A. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103478 · Cited by 17

Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice

Ziegler, C. G. K., Peng, M., Falk, M. J., Polyák, E., Tsika, E., Ischiropoulos, H., Bakalar, D., Blendy, J. A., & Gasser, D. L. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.09.011 · Cited by 16

Niacin for Parkinson's disease

Seamon, M., Purohit, S. B., Giri, B., Baban, B., Morgan, J. C., Chong, R. K. Y., & Wakade, C. G. (2019) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12553 · Cited by 16

Redox Neurology: Visions of an Emerging Subspecialty

Schipper, H. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.027 · Cited by 16

Oxidative Stress in Parkinson's Disease

Vaya, J., Aluf, Y., & Finberg, J. P. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-514-9_12 · Cited by 16

CSF Nrf2 and HSPA8 in Parkinson’s disease patients with and without LRRK2 gene mutations

Loeffler, D. A., Smith, L. M., Coffey, M. P., Aasly, J. O., & LeWitt, P. A. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1479-0 · Cited by 14

Mitochondrial Therapy for Parkinson Disease

Rosenberg, R. N. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1523 · Cited by 14

Mitochondrial electron transport chain defects modify Parkinson's disease phenotypes in a Drosophila model

O'Hanlon, M. E., Tweedy, C., Scialò, F., Bass, R., Sanz, A., & Smulders-Srinivasan, T. K. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105803 · Cited by 13

Platelet Mitochondrial Complex I and I+III Activities Do Not Correlate with Cerebral Mitochondrial Oxidative Metabolism

Powers, W. J., Haas, R., Le, T., Videen, T. O., Markham, J., & Perlmutter, J. S. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.179 · Cited by 13

Trial of subtherapeutic pergolide in de novo Parkinson's disease

Grosset, K. A., Grosset, D. G., & Lees, A. J. (2004) · Movement Disorders · doi:10.1002/mds.20361 · Cited by 13

Plasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

Biglan, K., for the Huntington Study Group Pre2CARE Investigators, Dorsey, E. R., Evans, R. V. V., Ross, C. A., Hersch, S. M., Shoulson, I., Matson, W. R., & Kieburtz, K. D. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-2012-120007 · Cited by 12

Serum levels of coenzyme Q in patients with Lewy body disease

Molina, J. A., de Bustos, F., Ortiz, S., del Ser, T., Seijo, M., Benito‐León, J., Oliva, J. M., Pérez, S., & Manzanares, J. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-001-0761-5 · Cited by 12

Lactate: A Theranostic Biomarker for Metabolic Psychiatry?

Caddye, E., Pineau, J., Reyniers, J., Ronen, I., & Colasanti, A. (2023) · Antioxidants · doi:10.3390/antiox12091656 · Cited by 11

Nanogels as controlled drug release systems for Coenzyme Q10 and Resveratrol for cosmetic application

Arroyo, E., Valdez, R., Cornejo‐Bravo, J. M., Armenta, M. A., & Olivas, A. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-021-05243-z · Cited by 11

Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression

Pienaar, I. S., & Chinnery, P. F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.010 · Cited by 11

The Evidence for Disease Modification in Parkinson's Disease

Lew, M. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.620194 · Cited by 11

The Impact of Coenzyme Q10 on Neurodegeneration: a Comprehensive Review

Kadian, M., Sharma, G., Pandita, S., Sharma, K., Shrivasatava, K., Saini, N., & Kumar, A. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-021-00273-6 · Cited by 11

Oxidative Stress and Parkinson Disease

Lim, K., Graham, D. G., & Ng, X. (2011) · Wiley eBooks · doi:10.1002/9781118148143.ch10 · Cited by 11

Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying

KONES, R. J. (2010) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s12082 · Cited by 11

Pharmacological approaches to disease-modifying therapies in Parkinson’s disease

O’Neill, M. J., & Siemers, E. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.6.819 · Cited by 10

Parkinson's Disease and Mitotherapy-Based Approaches towards α-Synucleinopathies

Bhatt, V., Shukla, H., & Tiwari, A. K. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2306109 · Cited by 9

Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: A possible complication of chronic hypoxia and carbon monoxide toxicity?

Lassinger, B. K., Kwak, C. H., Walford, R. L., & Jankovic, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20076 · Cited by 9

Nutraceuticals and Other Natural Products in Parkinson’s Disease Therapy

Mythri, R. B., Joshi, A. K. R., & Bharath, M. M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411462-3.00044-8 · Cited by 9

Neuroprotective potential of coenzyme Q10

Tripathi, S., Mishra, R., & Singh, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00057-9 · Cited by 9

Coenzyme Q10 supplementation improves adipokine profile in dyslipidemic individuals: a randomized controlled trial

Zhang, P., Chen, K., He, T., Guo, H., & Chen, X. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00649-5 · Cited by 10

Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease

Rasmussen, H. E., Piazza, B., Forsyth, C. B., & Keshavarzian, A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_11 · Cited by 9

Retinal coenzyme Q in the bovine eye

Qu, J., Ma, L. M., & Washington, I. (2011) · BioFactors · doi:10.1002/biof.166 · Cited by 8

Effects of Coenzyme Q10 Administration in Amyotrophic Lateral Sclerosis (ALS). Report of a Case and Review

Kawasaki, T. (2012) · The Open Nutraceuticals Journal · doi:10.2174/1876396001205010187 · Cited by 8

The impact of newly proposed dietary supplement manufacturing guidelines on patient safety and clinical trials outcomes

Kroll, D. J., & Oberlies, N. H. (2003) · Focus on Alternative and Complementary Therapies · doi:10.1211/fact.2003.00303 · Cited by 8

Onion‐Mitochondria Inhibit Lipopolysaccharide‐Induced Acute Lung Injury by Shaping Lung Macrophage Mitochondrial Function

Xu, Q., Teng, Y., Huang, Y., Mu, J., Teng, L. A., Qian, H., Huang, Q., Liu, M., Zou, Y., Zhang, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202506107 · Cited by 7

Anti-oxidants as therapeutic agents for oxidative stress associated pathologies: future challenges and opportunities

Nandha, S. R., Checker, R., Patwardhan, R. S., Sharma, D., & Sandur, S. K. (2025) · Free Radical Research · doi:10.1080/10715762.2025.2450504 · Cited by 9

CoenzymeQ10 localizations in model membranes. A Langmuir monolayer study

Nerdal, W., Nilsen, T. R. S., & Steinkopf, S. (2015) · Biophysical Chemistry · doi:10.1016/j.bpc.2015.09.003 · Cited by 7

Increasing coenzyme Q 10 yield from Rhodopseudomonas palustris by expressing rate‐limiting enzymes and blocking carotenoid and hopanoid pathways

Xu, W., Ma, X., Yao, J., Wang, D., Li, W., Liu, L., Shao, L., & Wang, Y. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13479 · Cited by 7

Cellular Models for Primary CoQ Deficiency Pathogenesis Study

Santos‐Ocaña, C., Cascajo, M. V., Alcázar‐Fabra, M., Staiano, C., López‐Lluch, G., Brea‐Calvo, G., & Navas, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910211 · Cited by 7

Coenzyme Q10: A Review of Essential Functions

(2005) · The Internet Journal of Nutrition and Wellness · doi:10.5580/872 · Cited by 7

Parkinson’s Disease

Simmons, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00015-3 · Cited by 7

Antioxidants as Therapy for Parkinson's Disease

Shults, C. W. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.694 · Cited by 7

Protection of Malonate-Induced GABA But Not Dopamine Loss by GABA Transporter Blockade in Rat Striatum

Zeevalk, G. D., Manzino, L., & Sonsalla, P. K. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7917 · Cited by 7

Opposite Roles of Co-enzyme Q10 and Formaldehyde in Neurodegenerative Diseases

Xu, J., Jin, X., Ye, Z., Wang, D., Zhao, H., & Tong, Z. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221143274 · Cited by 6

Statins Induce Locomotion and Muscular Phenotypes in Drosophila melanogaster That Are Reminiscent of Human Myopathy: Evidence for the Role of the Chloride Channel Inhibition in the Muscular Phenotypes

Al-Sabri, M. H., Behare, N., Alsehli, A. M., Berkins, S., Arora, A., Antoniou, E., Moysiadou, E. I., Anantha-Krishnan, S., Cosmen, P. D., Vikner, J., et al. (2022) · Cells · doi:10.3390/cells11223528 · Cited by 5

Effect of antioxidant‐enriched foods on plasma Coenzyme Q10 and total antioxidant capacity

Arsenio, L., Caronna, S., Dall’Aglio, E., Frega, N. G., Pacetti, D., Boselli, E., Tiano, L., Principi, F., & Littarru, G. P. (2008) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.200700303 · Cited by 6

Coenzyme Q 10 : functional benefits, dietary uptake and delivery mechanisms

Amar‐Yuli, I., Aserin, A., & Garti, N. (2009) · Elsevier eBooks · doi:10.1533/9781845696603.3.663 · Cited by 5

The effects of Coenzyme Q10 on locomotor and behavioral activity in young and aged C57BL/6 mice

Sinatra, D. S., Sinatra, S. T., & Heyser, C. J. (2003) · BioFactors · doi:10.1002/biof.5520180232 · Cited by 5

Mitochondrial Nutrition as a Strategy for Neuroprotection in Parkinson′s Disease—Research Focus in the Department of Alternative Medicine and Experimental Therapeutics at Hokuriku University

Mitsumoto, Y. (2007) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nel115 · Cited by 5

Statininduziertes Parkinson-Syndrom

Müller, T. (2003) · Der Nervenarzt · doi:10.1007/s00115-003-1528-z · Cited by 5

Central Nervous System ( CNS )

Sommer, D. B., & Goldstein, L. B. (2014) · Wiley StatsRef: Statistics Reference Online · doi:10.1002/9781118445112.stat06913 · Cited by 5

Future therapies for Parkinson's disease

Hauser, R. A., & Lyons, K. E. (2004) · Neurologic Clinics · doi:10.1016/j.ncl.2004.05.005 · Cited by 5

The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review

Pan, P., Zhou, N., Sun, Y., Chen, Z., Han, J.-Y., & Zhou, W. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1410133 · Cited by 5

Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues

Lin, W., & Kang, U. J. (2005) · Journal of Clinical Neurology · doi:10.3988/jcn.2005.1.2.107 · Cited by 4

Medical Treatment of Parkinson Disease

Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50009-7 · Cited by 4

Use of Mri to Monitor Parkinson’s Disease

Planetta, P. J., Prodoehl, J., Corcos, D. M., & Vaillancourt, D. E. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.10.6 · Cited by 3

The link between mitochondria, psychopathology, and intelligence: A bioenergetic model of cerebral functionPreprint

Fissler, P., Mavioğlu, R. N., Wenzel, M., Filippi, M., Stoewer, S., Wolff, W., Karabatsiakis, A., Pruessner, J. C., Kolassa, I., & Krähenmann, R. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/b3qf5 · Cited by 4

Coenzyme Q10 as an antioxidant in the elderly

Yubero‐Serrano, E. M., Gutierrez-Mariscal, F. M., García‐Ríos, A., Delgado‐Lista, J., Pérez‐Martínez, P., Camargo, A., Pérez‐Jiménez, F., & López‐Miranda, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818698-5.00016-x · Cited by 3

Mitochondrial respiration defects in lymphoblast cell lines from patients with Dravet syndrome

Figueroa, A. G., Fulton, R. E., Banerji, R., Knupp, K. G., & Patel, M. N. (2025) · Epilepsia · doi:10.1111/epi.18382 · Cited by 3

Electron Transport Chain

Aerts, L., & Morais, V. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00002-x · Cited by 3

Coenzyme Q10 as an Antioxidant in the Elderly

Yubero‐Serrano, E. M., García‐Ríos, A., Delgado‐Lista, J., Pérez‐Martínez, P., Camargo, A., Pérez‐Jiménez, F., & López‐Miranda, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405933-7.00011-1 · Cited by 3

The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction

Tie, J., Li, S., Huang, X., Ren, K., Ni, Z., Li, X., Zhu, C., Liu, H., Wu, F., Yang, Y., et al. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00552-6 · Cited by 2

The Effect of Simvastatin Treatment on Plasma Ubiquinone, Blood ATP Concentrations, Total Antioxidant Capacity and Muscle Related Markers

Altekin, E. (2002) · DergiPark (Istanbul University) · Cited by 2

Coenzyme q10: koenzim q10

GÜRKAN, A. S., & Dündar, O. B. (2005) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.1501/eczfak_0000000022 · Cited by 2

Coenzyme Q10 Stabilizes Mitochondria in Parkinson’s Disease

Ebadi, M., SHARMA, S. K., Wanpen, S., Shaik, S., & Refaey, H. E. (2005) · Oxidative stress and disease · doi:10.1201/9781420027174.ch12 · Cited by 2

Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases

Alcain, F. J., Domínguez, J., Durán‐Prado, M., & Vaamonde, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-45642-9_12 · Cited by 2

Biochemical and Pharmacological Properties of Coenzyme Q Analogs

Mordente, A., Martorana, G. E., Giardina, B., Meucci, E., & Minotti, G. (2000) · Modern nutrition · doi:10.1201/9781420036701.ch10 · Cited by 2

Transferrin, insulin, and progesterone modulate intracellular concentrations of coenzyme Q and cholesterol, products of the mevalonate pathway, in undifferentiated PC12 cells

Nakamura, A., Aida, Y., Okamoto, M., Maeda, A., Nagao, A., Kitatani, K., Takekoshi, S., Fujisawa, A., Yamamoto, Y., & Kashiba, M. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-115 · Cited by 1

PARK2 Induces Autophagy Removal of Impaired Mitochondria via Ubiquitination

Lim, K., Chua, D. S. K., Gallart‐Palau, X., & Yao, T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405528-5.00011-0 · Cited by 1

Parkinson’s Disease: Possible Mechanisms for Nutritional Approaches

Cherpak-Castagna, C. E., & Lare, S. J. V. (2020) · Journal of Restorative Medicine · doi:10.14200/jrm.2020.0104 · Cited by 1

Perspective Chapter: Nutraceuticals as a Therapeutic Promise in Healthy Aging and Neurocognitive Disorders

Ramesh, A., & Banerjee, D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104932 · Cited by 1

Mitochondrial Bioenergetics in Slow and Fast Growing Preimplantation Bovine Embryos

Merrill, C. (2016) · The Atrium (University of Guelph) · Cited by 1

Biochemical Diagnosis of Mitochondrial Disorders

Yubero, D., Montero, R., & Artuch, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-70147-5_8 · Cited by 1

Advances in Neuroprotection Research for Neurodegenerative Diseases

Götz, M. E., & Riederer, P. F. (2004) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8969-7_1 · Cited by 1

The Effects of Paraquat Exposure on Serial Reaction Time Performance in Rats (Rattus norvegicus) and Neuroprotection by Water-Soluble COQ10

Parameswaran, V. (2011)

Manifestations of Drug Toxicity on Mitochondria in the Nervous System

Reynolds, I. J. (2008) · Wiley eBooks · doi:10.1002/9780470372531.ch8

Population-based studies on the epidemiology of migraine and Parkinson's disease

Becker, C. (2007) · edoc (University of Basel) · doi:10.5451/unibas-004370546

Prospects for Neuroprotective Therapies that can Modulate Non‐Dopaminergic Features in Parkinson's Disease

Olanow, C. W., & Lang, A. E. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch39

Current and potential treatments of Parkinson's disease

Shults, C. W. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.043

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

Shults, C. W., Haas, R., & Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090223 · Cited by 91

Altered redox state of platelet coenzyme Q 10 in Parkinson's disease

Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93

Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10

SHARMA, S. K., Refaey, H. E., & Ebadi, M. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.11.019 · Cited by 56

Therapeutic role of coenzyme Q10 in Parkinson's disease

Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 81

Coenzyme Q10 shows promise for PD

Love, R. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00246-6 · Cited by 1